Kateri Moore, DVM
- PROFESSOR | Cell, Developmental & Regenerative Biology
Research Topics:
Aging, Bioinformatics, Cell Adhesion, Cell Biology, Cell Cycle, Cell Division, Cellular Differentiation, Developmental Biology, Epigenetics, Gene Discovery, Genomics, Hematopoiesis, Mathematical Modeling of Biomedical Systems, Molecular Biology, Stem Cells, Transcription Factors, Transgenic MiceMy laboratory is studying both the basic biology and molecular mechanisms that make a hematopoietic stem cell a self-renewing stem cell that sustains our blood system throughout life. We do this by investigating these properties in model systems and by trying to convert other cell types into hematopoietic stem cells for eventual therapeutic uses. https://neuroscience.mssm.edu/DLabs/labs/lm.html
Multi-Disciplinary Training Area
Development, Regeneration, and Stem Cells [DRS]Education
BS, Kansas State University
DVM, Kansas State University
Post Doctoral, Baylor College of Medicine
-
2014
R01 HL119404-01A1 -
1988
National Research Service Award
Hematopoietic Stem Cells Normal and Reprogrammed
Specific Clinical/Research Interest: Stem Cells/Microenvironment/Stem Cell Niche, Molecular regulation of hematopoietic stem cell self renewal and differentiation, molecular interaction of stem cells and microenvironmental elements. Direct differentiation of somatic cells into hematopoietic stem cells.
Current Students: Jeffrey Bernitz
Michael Daniel
Andreia Gomes
Research Personnel: Ying Liu
Summary of Research Studies: Primary research interest is in defining the cellular and molecular nature of the hematopoietic stem cells (HSCs) and in particular the molecular cross-talk between stem cells and their niche. Approach is to use mouse models to study HSC during normal homeostasis and after stress. Also using specific factors to directly induce HSCs from somatic cells to develop patient specific stem cells and differentiated blood products for cell replacement therapies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Moore did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.